Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
NCT06553885Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2025
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in colorectal cancer (CRC), hepatocellular carcinoma (HCC), sponsored by Moffitt Cancer Center. Started Apr 2025; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06553885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553885.